This article is based on a single case report published in Frontiers in Neuroscience. Case reports cannot establish causality, and the findings should not be generalized to the broader Alzheimer’s population. See caveats below.
An octogenarian woman with a 10-year history of advanced Alzheimer’s disease became conversational for several hours after consuming five grams of Enigma strain Psilocybe cubensis mushrooms, according to a case report published in Frontiers in Neuroscience. The improvement was sustained over subsequent weeks and even deepened after a second lower dose, but the authors described the effects as transient, not a reversal of disease pathology.
The report, by Marcos Lago and colleagues at the Associação Cruz de Ankh in Sao Paulo, Brazil, describes a patient who had been in marked functional decline for five years: monosyllabic speech only, chronic urinary incontinence, difficulty swallowing, dependent mobility, and a flat affect. She required full-time care.
What happened
Approximately 19 hours after the first dose, the patient emerged from a deep sleep-like state and initiated approximately four hours of autobiographical conversation, recalling memories and events she had not expressed in years. Over the following days and weeks, additional improvements emerged: sustained eye contact, reciprocal smiling, independent walking, dressing herself, and regained urinary continence including at night.
One month later, a second dose of three grams of the same mushroom strain produced even greater verbal expressivity, humor, improved facial mimicry, and gait agility.
The authors used the word “transient” in the title of their paper. The improvements were observed over weeks but the report does not describe long-term follow-up beyond the documented period. Some effects, such as continence, appeared to persist between the two sessions.
Why this is preliminary
The report is a single case study with no control, no blinding, no standardized cognitive assessments, no neuroimaging, and no formal biomarker confirmation of Alzheimer’s pathology. The diagnosis was based on clinical symptoms, not amyloid or tau PET, CSF biomarkers, or autopsy. Mixed pathologies including vascular dementia or Lewy body disease cannot be ruled out.
Crucially, the patient could not consent to the intervention. Consent was obtained from her son. Albert Garcia-Romeu at Johns Hopkins University, quoted in the New Scientist article, raised concerns about both the validity and ethics of the study given the patient’s inability to provide informed consent.
No formal cognitive scales were administered. No polysomnography, electrophysiology, or cardiovascular monitoring was performed during the acute psilocybin session. The improvements, while striking in the descriptive account, were not measured quantitatively.
A neuromodulation effect, not a disease reversal
The authors frame the result not as a reversal of Alzheimer’s pathology but as temporary access to latent functional capacity through neuromodulation. Psilocybin is known to increase brain network flexibility and connectivity, particularly between the default mode network and other large-scale brain networks. In advanced Alzheimer’s, where neural circuits are damaged but not entirely destroyed, even a transient increase in network plasticity could temporarily unmask preserved cognitive function.
This interpretation is consistent with the transient nature of the improvement. The patient did not show sustained recovery beyond the documented weeks, and the underlying neurodegenerative process would be expected to continue.
What it does not mean
A single positive case report does not constitute evidence that psilocybin is a treatment for Alzheimer’s disease. Spontaneous fluctuations occur in neurodegenerative disease. No causal mechanism was established. The improvement could reflect placebo response in the family or caregiver, confirmation bias, or natural variability in the disease course.
The study also used whole mushrooms rather than purified psilocybin, introducing unknown variables from other psychoactive compounds present in the fungal material.
What’s next
The case report may generate hypotheses for more rigorous investigation, but it does not warrant clinical action. Any future studies would need to be controlled, blinded, include standardized cognitive assessments and biomarkers, and address the substantial ethical challenges of psychedelic administration in patients who cannot consent.
Several clinical trials of psilocybin in major depressive disorder are already in late-stage development, including a Phase 3 trial of Definium’s LSD therapy DT120 reported this week by STAT News. Whether similar approaches could be applied to dementia populations remains a distant and ethically complicated question.
Source: Lago, M., Cerveira, M., & Simonet, J.X. Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report. Frontiers in Neuroscience, 20, Article 1813281 (2026). DOI: 10.3389/fnins.2026.1813281
Disclosure: Based on a single case report, not a clinical trial. Findings cannot establish causality or be generalized.